# Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

> **NCT04304820** · PHASE2 · RECRUITING · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 80 (estimated)

## Conditions studied

- Severe Aplastic Anemia

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** Cyclosporine
- **DRUG:** Horse-Anti-thymocyte-Globulin

## Key facts

- **NCT ID:** NCT04304820
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-05-07
- **Primary completion:** 2024-12-18
- **Final completion:** 2033-12-18
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04304820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04304820, "Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04304820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*